MX2022008073A - Anticuerpos dirigidos a los huesos. - Google Patents

Anticuerpos dirigidos a los huesos.

Info

Publication number
MX2022008073A
MX2022008073A MX2022008073A MX2022008073A MX2022008073A MX 2022008073 A MX2022008073 A MX 2022008073A MX 2022008073 A MX2022008073 A MX 2022008073A MX 2022008073 A MX2022008073 A MX 2022008073A MX 2022008073 A MX2022008073 A MX 2022008073A
Authority
MX
Mexico
Prior art keywords
bones
antibodies directed
antibodies
fragments
poly
Prior art date
Application number
MX2022008073A
Other languages
English (en)
Inventor
Huawei Qiu
Sunghae Park
James Stefano
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2022008073A publication Critical patent/MX2022008073A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan anticuerpos recombinantes y conjugados químicamente y fragmentos de los mismos modificados con uno o más péptidos poli-aspartato (poli-D) (p. ej., una secuencia D10) para mejorar la localización de los anticuerpos o fragmentos en hueso. También se describen métodos de fabricación y uso de estos anticuerpos y fragmentos.
MX2022008073A 2017-01-20 2019-07-17 Anticuerpos dirigidos a los huesos. MX2022008073A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762448763P 2017-01-20 2017-01-20

Publications (1)

Publication Number Publication Date
MX2022008073A true MX2022008073A (es) 2022-07-27

Family

ID=61581744

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008549A MX2019008549A (es) 2017-01-20 2018-01-19 Anticuerpos dirigidos a los huesos.
MX2022008073A MX2022008073A (es) 2017-01-20 2019-07-17 Anticuerpos dirigidos a los huesos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019008549A MX2019008549A (es) 2017-01-20 2018-01-19 Anticuerpos dirigidos a los huesos.

Country Status (17)

Country Link
US (3) US10844115B2 (es)
EP (1) EP3571226A2 (es)
JP (3) JP7227138B2 (es)
KR (3) KR102613463B1 (es)
CN (2) CN111032690B (es)
AR (1) AR110755A1 (es)
AU (1) AU2018210270A1 (es)
BR (1) BR112019013986A2 (es)
CA (1) CA3050884A1 (es)
IL (2) IL317592A (es)
MX (2) MX2019008549A (es)
MY (2) MY207919A (es)
SG (1) SG11201906663VA (es)
TW (3) TWI788321B (es)
UY (1) UY37576A (es)
WO (1) WO2018136698A2 (es)
ZA (1) ZA201907673B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190216943A1 (en) * 2016-08-11 2019-07-18 Precithera, Inc. Tgf-beta antagonist conjugates
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
AR110755A1 (es) * 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
BR112021000065A2 (pt) * 2018-07-10 2021-04-06 Sanofi Terapias de combinação contra câncer direcionando cd38 e tgf-beta
CA3120216A1 (en) * 2018-11-19 2020-05-28 Biocartis Nv Enhanced detection of low-copy-number nucleic acids in an integrated workflow
KR20240018471A (ko) 2021-05-07 2024-02-13 베이롤 칼리지 오브 메드신 중등증 내지 중증 불완전 골형성증의 치료
CN117999093A (zh) * 2021-07-20 2024-05-07 威廉马歇莱思大学 用于骨靶向治疗的经改造组合物
US20230144192A1 (en) 2021-11-01 2023-05-11 Genzyme Corporation Treatment of osteogenesis imperfecta
CN115403657A (zh) * 2022-06-23 2022-11-29 浙江大学 一种TGF-β3生长因子的亲和多肽及其应用
EP4673179A1 (en) 2023-02-27 2026-01-07 William Marsh Rice University Bone-directed therapeutics for the treatment of cancer
JP7479537B1 (ja) * 2023-03-31 2024-05-08 ナガヨシ製薬株式会社 咳を止め、痰を減らし、免疫力を向上させるイナゴマメ多糖類およびその調製方法と使用
WO2025184427A1 (en) * 2024-02-27 2025-09-04 Osteologic Therapeutics, Inc. Bone-targeted antibodies and methods of use thereof
CN120647762B (zh) * 2025-06-16 2026-01-23 首都医科大学附属北京友谊医院 一种抗β1-AR-ECII抗体及其应用
CN120535618B (zh) * 2025-07-28 2025-09-23 成都大熊猫繁育研究基地 一种抗大熊猫cdv单克隆抗体、杂交瘤细胞株及用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
EP1074563A1 (en) * 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
KR20050094832A (ko) * 2002-12-31 2005-09-28 알투스 파마슈티컬스 인코포레이티드 단백질 결정과 이온성 중합체를 함유하는 복합체
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
CA2632799A1 (en) * 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
EA021967B1 (ru) * 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
US20120294868A1 (en) * 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP2714735B1 (en) 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
KR20140084201A (ko) * 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) * 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
MX361773B (es) * 2012-05-31 2018-12-17 Innate Pharma Agentes de ligación a tlr3.
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CA2886607A1 (en) 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
AU2014235933B2 (en) * 2013-03-20 2019-01-24 Baylor College Of Medicine Methods for treating osteogenesis imperfecta
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
ES2763429T5 (es) 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
EP3119419B1 (en) * 2014-03-17 2019-04-03 Piotr Jachimczak Combination for use in a method of treating cancer
CN107428825A (zh) 2014-10-10 2017-12-01 创祐生技股份有限公司 治疗及/或预防肿瘤生长、侵袭及/或转移的方法
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
WO2017011773A2 (en) * 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
US20190216943A1 (en) * 2016-08-11 2019-07-18 Precithera, Inc. Tgf-beta antagonist conjugates
AR110755A1 (es) * 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途

Also Published As

Publication number Publication date
US20250074975A1 (en) 2025-03-06
KR102755284B1 (ko) 2025-01-22
KR102613463B1 (ko) 2023-12-15
US12098194B2 (en) 2024-09-24
TWI788321B (zh) 2023-01-01
IL317592A (en) 2025-02-01
IL268114B1 (en) 2025-01-01
MY194819A (en) 2022-12-17
CA3050884A1 (en) 2018-07-26
ZA201907673B (en) 2021-05-26
WO2018136698A2 (en) 2018-07-26
SG11201906663VA (en) 2019-08-27
JP2025028981A (ja) 2025-03-05
IL268114B2 (en) 2025-05-01
EP3571226A2 (en) 2019-11-27
US10844115B2 (en) 2020-11-24
KR20250012197A (ko) 2025-01-23
IL268114A (en) 2019-09-26
RU2019126026A3 (es) 2021-11-09
KR20230172039A (ko) 2023-12-21
TW201839013A (zh) 2018-11-01
JP7227138B2 (ja) 2023-02-21
UY37576A (es) 2018-10-31
US20180208650A1 (en) 2018-07-26
WO2018136698A3 (en) 2018-08-30
JP7597836B2 (ja) 2024-12-10
CN111032690A (zh) 2020-04-17
JP2020505919A (ja) 2020-02-27
AR110755A1 (es) 2019-05-02
MX2019008549A (es) 2019-09-11
TWI832600B (zh) 2024-02-11
AU2018210270A1 (en) 2019-09-05
TW202421659A (zh) 2024-06-01
KR20190105236A (ko) 2019-09-16
RU2019126026A (ru) 2021-02-20
TW202330597A (zh) 2023-08-01
CN111032690B (zh) 2024-03-26
JP2023058590A (ja) 2023-04-25
CN118121696A (zh) 2024-06-04
MY207919A (en) 2025-03-27
BR112019013986A2 (pt) 2020-03-03
US20210163584A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
MX2019008549A (es) Anticuerpos dirigidos a los huesos.
PE20220256A1 (es) Sistemas de casx artificiales
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
CO2020000774A2 (es) Rellenos de tejidos basados en ácido hialurónico de seda y métodos de utilizar los mismos
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CL2021001542A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
MX2019003445A (es) Proteinas de fusion inmunomoduladoras.
CO2018011668A2 (es) Neoantígenos y métodos de su uso
ZA202103511B (en) Engineered robust high tm-phytase clade polypeptides and fragments thereof
CO2019010503A2 (es) Plataforma de identificación de péptidos inmunogénicos personalizada
UY40283A (es) Método para alterar una propiedad de una planta
CL2019002134A1 (es) Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas.
MX2025001906A (es) Construcciones de anticuerpos anti-ror
MX2020000960A (es) Anticuerpos anti-tigit.
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
UY36862A (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2017008660A (es) Polipeptidos enlazados a il-17a.
MX2020003672A (es) Proteinas de fusion inmunomoduladora.
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
IL277632A (en) CDNF fragments from the carboxyl end, pharmaceutical compositions containing them and their uses
MX390927B (es) Partículas semejantes a virus recombinantes que utilizan la proteína gag del virus de inmunodeficiencia bovina.